Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Integrin Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Integrin Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Integrins, a diverse family of cell adhesion molecules, are crucial mediators in numerous cellular processes by facilitating interactions between cells and the extracellular matrix. These cell adhesion molecules are present on the cell surfaces of various cell types, including epithelial cells, endothelial cells, immune cells, platelets, and fibroblasts, among others. Integrins are essential for cell-to-cell adhesion, cell-to-extracellular matrix interactions, and signal transduction processes, making them ubiquitous in multiple tissues and organs. Comprised of α and β subunits, integrins bind to specific ligands, such as fibronectin and collagen, initiating intracellular signaling cascades. This conformational change triggers the formation of focal adhesions, stabilizing cell-substrate attachments. Integrins play a pivotal role in diverse physiological and pathological conditions. Promisingly, they are utilized in cancer therapy, where integrin-targeted treatments have shown potential in combating metastasis. Furthermore, integrin antagonists have proven effective in addressing inflammatory disorders, such as rheumatoid arthritis. According to the World Health Organization, cancer remains a leading cause of death worldwide, with approximately 10 million deaths reported annually, highlighting the urgent need for effective integrin-based interventions to combat this devastating disease. Integrins' versatility and their involvement in various health conditions underscore their significance as potential targets for innovative therapeutic approaches. Extensive research is being conducted to find new and novel molecules to prevent and cure disease like Crohn’s disease. The development and launch of newer products by the market players will significantly enhance the revenue of the Integrin market over the forecast years.
A number of these inhibitors are in the market while many are in ongoing clinical trials. Companies in their pipelines have 104 products in various stages of clinical trials. 3 products are in Phase 4, 6 products in Phase 3 and 4 products are in the Phase 2 of the clinical trials.
Approved molecules
Drugs in Pipeline
Clinical Activity and Developments of Integrin
As of July 2023, 104 products for 378 diseases are in clinical trials. For instance,
|
Molecule name |
Number of studies |
|
Entyvio (vedolizumab) |
143 |
|
Tysabri (natalizumab) |
140 |
|
Isentress (raltegravir) |
332 |
|
Entyvio SC (vedolizumab SC) |
18 |
|
Cilcane (cilengitide) |
32 |
Integrins find applications in various medical indications, offering potential therapeutic benefits in various disease contexts. One prominent area where integrin-targeted therapies have shown significant promise is cancer treatment. By inhibiting specific integrins involved in tumor growth and metastasis, these therapies aim to impede cancer progression. Additionally, integrin antagonists have been explored for their potential in treating autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, by modulating immune responses. Integrin-based interventions have also been investigated for their potential to address fibrotic diseases, such as pulmonary and liver fibrosis, where aberrant tissue remodeling occurs. Furthermore, integrins play a crucial role in angiogenesis, making them attractive targets for anti-angiogenic therapies to hinder blood vessel formation in diseases like age-related macular degeneration and solid tumors. With their involvement in platelet function and thrombus formation, integrins are being explored as targets for antiplatelet therapies to prevent cardiovascular events. Collectively, these diverse indications highlight the wide-ranging potential of integrin-based therapies in addressing critical diseases and improving patient outcomes.
The global net sales of Isentress by Merck were $633 million in the financial year 2022, which was 18% less than the sales in 2021 of $769. The net sales in the 4th quarter of 2022 were $167 million, while in the 4th quarter of 2021 were $178 million. The product sales have seen a decline in the sales due to increasing competition and slower US Pharmaceutical market growth. According to a 2020 study, the global prevalence of rheumatoid arthritis is about 1% but varies by geography and latitude in Europe. Countries such as Sweden and Germany had prevalence rates of 0.65 percent, while France and Italy had a lower prevalence than global estimates of 0.19 percent and 0.41 percent, respectively. Variation in prevalence rates is also influenced by several factors, such as gender and environmental factors.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Isentress (raltegravir), Entyvio (vedolizumab), and Tysabri (natalizumab) are approved by the FDA.
These are being used in various indications like Inflammatory Bowel Disease (IBD), Crohn’s Disease (CD), Ulcerative Colitis (UC), Autoimmune diseases, and others.
Takeda Pharmaceutical, Biogen, Royalty Pharma, Iceni Pharmaceuticals, and Roche are some of the major market players for Integrin.
Rising incidence of diseases, improvement in technologies, development of new treatment lines in the market, and changing lifestyles leading to different types of disorders like Ulcerative Colitis and Inflammatory Bowel Disease are the key opportunities for Integrin in the market.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.